New Crestor� data in African-American patients with high cholesterol Part 2

Additional notes from ARIES demonstrated: -- CRESTOR 10 and 20 mg increased HDL-C via 7 and 6.5 percent equate essential 5.6 and 3.7 percent with atorvastatin 10 and 20 mg. CRESTOR 10 mg produced a excessive deal greater mount than 20 mg of atorvastatin (p<0.017) -- CRESTOR 10 and 20 mg reduced non-HDL-C by 34 and 42 percent compared with 30 and 36 percent all for atorvastatin at like dosage (p<0.017) -- CRESTOR 10 and 20 mg reduced unqualified cholesterol by 27 and 33 percent compared with 23 and 29 percent for atorvastatin 10 and 20 mg (p<0.017) African Americans and Elevated Cholesterol According to the American Heart Association, more or less 42 percent of the African-American population enjoy lofty cholesterol, and an inexact 45 percent has elevated LDL-C level.

Additionally, according to the National Center for Chronic Disease Prevention and Health Promotion's Risk Factor Surveillance System (BRFSS), an estimated 26 percent of the African-American population has never have their cholesterol levels checked.

"It is capably solid that AgRP [Agouti-related protein] neurons stage extravaganza a carping role in nurture and energy balance point of view," explains Qingchun Tong, PhD, a postdoctoral fellow in the Lowell laboratory and the study's first author. "However, the deletion of AgRP and NPY [two neuropeptides released from the AgRP neurons] robe paltry metabolic effect." An alternate guess proposed that secretion of the GABA neurotransmitter be mediate the run of AgRP neurons, an theory that had prolonged be postulate but never examine.

"Completion of enrollment in NB-301 is a switch tread in finance the Contrave program toward a intended FDA submission in tardy 2009," said Orexigen President and CEO, Gary Tollefson, M.D., Ph.D. "Our finishing two Phase III clinical trial be enrol by development of scheduled. Continued realization of our Phase III milestone would not be adequate minus the dedication and conscientiousness of the in depth Contrave nurturing legion." In November, Orexigen announced that enrollment be utter in the most primitive of its four Phase III clinical trials, NB-302. This is a 56-week placebo-controlled study designed to analyze the efficacy, safety and tolerability of Contrave when shared beside an intensive behavior inferior change protocol. This trial is taking place at nine centers nationwide and has enrol approximately 790 patients.